Loading asset research
Larimar Therapeutics Inc. Common Stock
LRMRNasdaq · USD · StocksQuote as of · Exchange session not verified$3.94
+2.34%
Today
LRMR
Loading 1D prices…
Market cap
$407.2M
Volume
2.1M
52w high
$6.4252w low
$2.71Company profile
Larimar Therapeutics Inc. Common Stock
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Bala Cynwyd, PA, United States
Employees
71
Fiscal year end
1231
CIK
1374690
Session & valuation
Open$3.91
Previous close$3.85
Day high$4.07
Day low$3.85
30-day avg. volume1M
Outstanding shares103.9M
Diluted EPS-$2.27
Latest annual period
P/E (trailing)-1.74
P/E (forward)-3.70
Price / book3.21
Beta0.75
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| RZLTRezolute Inc. Common Stock (NV) | $406.4M | $0.00 | — | -$0.55 | +0.96% | Buy |
| BBOTBridgeBio Oncology Therapeutics Inc. Common Stock | $396.9M | $0.00 | — | -$4.30 | -10.87% | Buy |
| ARCTArcturus Therapeutics Holdings Inc. Common Stock | $418.7M | $82M | -80.19% | -$2.40 | +5.33% | Buy |
| BNTCBenitec Biopharma Inc. Common Stock | $418.8M | $0.00 | — | -$0.72 | -0.25% | Buy |
| GALTGalectin Therapeutics Inc. Common Stock | $394.3M | $0.00 | — | -$0.48 | +0.38% | Buy |